CATANIA, Italy, Sept. 8, 2023 /PRNewswire/ -- SIFI, a leading international ophthalmic company, is pleased to announce the presentation of new scientific data on its products during the upcoming Congress of The European Society of Cataract and Refractive Surgeons (ESCRS) which will take place from September 8-12 in Vienna.
CATANIA, Italy, Jan. 10, 2023 /PRNewswire/ -- SIFI, a leading international ophthalmic company headquartered in Italy, today announced that it has partnered with Avanzanite Bioscience (Avanzanite), a Dutch specialty pharmaceutical company, to exclusively commercialize and distribute AKANTIOR® (polihexanide) in 26 Countries within the European Economic Area and Switzerland. Under the terms of the agreement, SIFI will handle all ongoing regulatory activities, whilst Avanzanite will focus on market access, distribution and commercial activities in those markets. The partnership will enable commercial access to AKANTIOR® to an estimated 500 patients who suffer from Acanthamoeba Keratitis (AK) each year in these territories.
CATANIA, Italy, Sept. 15, 2022 /PRNewswire/ -- SIFI, a leading international ophthalmic company, announces 3 scientific presentations on its latest innovations during the upcoming Congress of The European Society of Cataract and Refractive Surgeons (ESCRS) which will take place from 16th to 20th September in Milan (Italy). These presentations will feature the results of studies evaluating SIFI's advanced solutions for cataract refractive surgery.
CATANIA, Italy, Oct. 19, 2021 /PRNewswire/ -- SIFI, a leading international ophthalmic company, announced today that the pivotal Phase III study on polihexanide 0,08% monotherapy in adults and adolescents with Acanthamoeba keratitis (AK), met its primary endpoint of 'clinical resolution rate over a 12-month timeframe'. It also demonstrated an encouraging safety and tolerability profile. Based on these results, SIFI will request an accelerated assessment and plans to file a Marketing Authorisation Application (MAA) at the European Medicines Agency (EMA) for polihexanide 0,08% monotherapy under the Centralised Procedure for Orphan-Designated Medicinal Products in the first half of 2022.
SIFI, a leading international ophthalmic company focused on developing and commercializing innovative therapeutic solutions for patients with eye problems, announced today that it will be exhibiting at the upcoming 2021 BIO Digital ( from June 10 to 11 and June 14 to 18, 2021). To register for a one-on-one interview ™ with a company representative, please register here.